Results of a Randomized placebo-controlled study of memory training for mildly impaired Alzheimer's disease patients

被引:69
|
作者
Cahn-Weiner, DA
Malloy, PF
Rebok, GW
Ott, BR
机构
[1] Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI USA
[2] Mem Hosp Rhode Isl, Pawtucket, RI USA
[3] Butler Hosp, Providence, RI 02906 USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA
[5] Brown Med Sch, Dept Clin Neurosci, Providence, RI USA
来源
APPLIED NEUROPSYCHOLOGY | 2003年 / 10卷 / 04期
关键词
memory training; Alzheimer's Disease; randomized placebo-controlled;
D O I
10.1207/s15324826an1004_3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The efficacy of a memory-training program to improve word-list recall and recognition was evaluated in 34 patients with probable Alzheimer's disease (AD). The patients, who were all taking donepezil throughout the 6-week intervention, were randomly assigned to a cognitive intervention group or a control group. The Control group received didactic presentations but no formal memory training. Patients were assessed on neuropsychological tests before the 6-week training program, immediately after the training, and 8 weeks after completion of the training. Caregivers, who were blind to group assignment, completed activities of daily living (ADLs) and everyday memory questionnaires at all three timepoints. No significant main effects of group (training vs. control) or time were observed on any outcome measures, nor were any significant interactions found. In terms of "process" measures during the 6-week training program, the patients demonstrated modest improvement on recall and recognition of test material presented during the training sessions. These results suggest that although modest gains in learning and memory may be evident in AD patients who are taught specific strategies, the benefits do not generalize to other measures of neuropsychological functioning after a brief intervention.
引用
收藏
页码:215 / 223
页数:9
相关论文
共 50 条
  • [32] Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study
    Doody, Rochelle
    Gavrilova, Svetlana
    Sano, Mary
    Thomas, Ronald
    Aisen, Paul
    Seely, Lynn
    Hung, David
    NEUROLOGY, 2007, 68 (12) : A353 - A353
  • [33] Randomized, placebo-controlled, double-blind clinical trial of sertraline in the treatment of depression complicating Alzheimer's disease: Initial results from the depression in Alzheimer's disease study
    Lyketsos, CG
    Sheppard, JME
    Steele, CD
    Kopunek, S
    Steinberg, M
    Baker, AS
    Brandt, J
    Rabins, PV
    AMERICAN JOURNAL OF PSYCHIATRY, 2000, 157 (10): : 1686 - 1689
  • [34] Double-blind placebo-controlled study of velnacrine in Alzheimer's disease
    Zemlan, FP
    Keys, M
    Richter, RW
    Strub, RL
    LIFE SCIENCES, 1996, 58 (21) : 1823 - 1832
  • [35] Analyses of natural courses of Japanese patients with Alzheimer's disease using placebo data from placebo-controlled, randomized clinical trials: Japanese Study on the Estimation of Clinical course of Alzheimer's disease
    Watanabe, Mitsunori
    Nakamura, Yu
    Yoshiyama, Yasumasa
    Kagimura, Tatsuo
    Kawaguchi, Hiroyuki
    Matsuzawa, Hiroshi
    Tachibana, Yosuke
    Nishimura, Kazuma
    Kubota, Naoki
    Kobayashi, Masato
    Saito, Takayuki
    Tamura, Kaoru
    Sato, Takayuki
    Takahashi, Masayoshi
    Homma, Akira
    ALZHEIMERS & DEMENTIA-TRANSLATIONAL RESEARCH & CLINICAL INTERVENTIONS, 2019, 5 (01) : 398 - 408
  • [36] A 25-week placebo-controlled study of eptastigmine in patients with Alzheimer disease
    Imbimbo, BP
    Lucca, U
    Lucchelli, F
    Alberoni, M
    Thal, LJ
    ALZHEIMER DISEASE & ASSOCIATED DISORDERS, 1998, 12 (04): : 313 - 322
  • [37] Trazodone Improves Sleep Parameters in Alzheimer Disease Patients: A Randomized, Double-Blind, and Placebo-Controlled Study
    Camargos, Einstein F.
    Louzada, Luciana L.
    Quintas, Juliana L.
    Naves, Janeth O. S.
    Louzada, Fernando M.
    Nobrega, Otavio T.
    AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY, 2014, 22 (12): : 1565 - 1574
  • [38] A Phase 2, Randomized, Placebo-Controlled Trial to Evaluate the Effects of SAGE-718 in Patients with Alzheimer's Disease: Study Design
    Lago, Tiffany
    Koenig, Aaron
    Johannesen, Jason
    Park, Sola
    Li, Sigui
    Freitag, Emily
    Wald, Jeffrey
    Paumier, Katrina
    Quirk, Michael
    Doherty, James
    NEUROLOGY, 2023, 100 (17)
  • [39] A double-blind, placebo-controlled study of tacrine in patients with Alzheimer's disease using SPET
    Prentice, N
    VanBeck, M
    Dougall, NJ
    Moffoot, APR
    OCarroll, RE
    Goodwin, GM
    Ebmeier, KP
    JOURNAL OF PSYCHOPHARMACOLOGY, 1996, 10 (03) : 175 - 181
  • [40] A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
    Tariot, PN
    Cummings, JL
    Katz, IR
    Mintzer, J
    Perdomo, CA
    Schwam, EM
    Whalen, E
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2001, 49 (12) : 1590 - 1599